DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Analyst Ratings
USA - NASDAQ:DAWN - US23954D1090 - Common Stock
9.73 USD
+0.74 (+8.23%)
9.75 USD
+0.02 (+0.21%)
ChartMill assigns a Buy % Consensus number of 83% to DAWN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 23.72. This target is 143.73% above the current price.
DAWN was analyzed by 16 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about DAWN.
In the previous month the buy percentage consensus was at a similar level.
DAWN was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-07 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-05 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-08-06 | Needham | Maintains | Buy -> Buy |
| 2025-08-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-07 | Needham | Maintains | Buy -> Buy |
| 2025-04-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-03-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-02-26 | Needham | Reiterate | Buy -> Buy |
| 2025-02-26 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-02-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-10 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-01-13 | Needham | Reiterate | Buy -> Buy |
| 2025-01-07 | B of A Securities | Maintains | Buy -> Buy |
| 2024-12-17 | Jones Trading | Maintains | Buy -> Buy |
| 2024-10-31 | Needham | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-09 | Needham | Maintains | Buy -> Buy |
| 2024-08-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-08-01 | B of A Securities | Upgrade | Underperform -> Buy |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-31 | Needham | Maintains | Buy -> Buy |
| 2024-07-30 | Needham | Reiterate | Buy -> Buy |
| 2024-07-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-08 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-06-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-19 | Needham | Reiterate | Buy -> Buy |
| 2024-05-07 | Needham | Reiterate | Buy -> Buy |
| 2024-05-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-04-25 | Needham | Reiterate | Buy -> Buy |
DAY ONE BIOPHARMACEUTICALS I / DAWN FAQ
Can you provide the average price target for DAY ONE BIOPHARMACEUTICALS I stock?
16 analysts have analysed DAWN and the average price target is 23.72 USD. This implies a price increase of 143.73% is expected in the next year compared to the current price of 9.73.
How do analysts rate DAY ONE BIOPHARMACEUTICALS I (DAWN)?
The consensus rating for DAY ONE BIOPHARMACEUTICALS I (DAWN) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed DAY ONE BIOPHARMACEUTICALS I (DAWN)?
The number of analysts covering DAY ONE BIOPHARMACEUTICALS I (DAWN) is 16.